GLPG VS BHC Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

GLPG
75/100

GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.

BHC
10/100

BHC returned -4.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

GLPG
78/100

8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.

BHC

"Analyst Price Targets" not found for BHC

Technicals

GLPG
71/100

GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

BHC
11/100

BHC receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

GLPG
10/100

GLPG has missed earnings 10 times in the last 20 quarters.

BHC
10/100

BHC has missed earnings 6 times in the last 20 quarters.

Profit

GLPG
40/100

Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.

BHC
32/100

Out of the last 20 quarters, BHC has had 5 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

GLPG
50/100

GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

BHC
50/100

BHC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Galapagos NV Summary

Nasdaq / GLPG
Healthcare
Biotechnology
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Bausch Health Companies Inc. Summary

New York Stock Exchange / BHC
Healthcare
Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.